News Detail

BioQ Pharma and POA Pharma Announce Strategic Partnership to Commercialize Three Ready-to-Use Infusion Products in the Nordic Region

May 29, 2018

SAN FRANCISCO, May 30, 2018: BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, and POA Pharma Scandinavia AB (“POA”), a market oriented Boutique Healthcare Company, working in close contact with healthcare organizations, professionals and pharmacies in Nordic countries, today announced a strategic agreement to commercialize three ready-to-use infusion products in Denmark, Finland, Norway, Sweden and Iceland.

The three-product collaboration between POA and BioQ includes Ropivacaine ReadyfusOR, an opioid sparing post-surgical pain management therapy, as well as two other product candidates. Ropivacaine ReadyfusOR is indicated for postoperative pain treatment in adults. It is a ready-to-use, single use infusion product, pre-filled by the manufacturer with 250 ml 0.2% Ropivacaine and provides over 48 hours of postoperative pain treatment. Ropivacaine ReadyfusOR is indicated for both continuous wound site infusion and continuous peripheral nerve block.

Josh Kriesel, President and CEO of BioQ Pharma, commented, “The company is very pleased to announce this commercial collaboration with POA to introduce our line of self-contained infusible pharmaceutical products into the Nordics. We welcome the opportunity to partner with a marketing partner of POA’s caliber in the region.”

Tina Madsen Sandstrőm, CEO of POA, said “POA Pharma is looking forward to offering these pain and anesthesia ready-to-use products to our patients and clinical customers in the Nordic markets. We are happy to once again have the opportunity to introduce new and innovative developments to the health care sector.”

About BioQ Pharma

BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Stada, Cipla, Lee's Pharm, Lunatus, Galen Limited, POA Pharma, and West Pharmaceutical Services.

About POA Pharma

POA Pharma is a market oriented Boutique Healthcare Company present in 9 competence areas with offices in Denmark, Finland, Norway, Sweden and US. The home Market is the Nordic countries were POA represents 12 Pharmaceutical producers from 10 countries. Our export is based on POA proprietary products, classified as Food for specific medical Purposes, products that are sold in more than 40 countries.

Company Contact Information:

Tina Madsen Sandstrőm
POA Pharma Scandinavia AB
+46 31 7880599

Josh Kriesel
BioQ Pharma Incorporated
President and CEO

Ron Pauli
BioQ Pharma Incorporated
Chief Financial Officer

Walter Cleymans
BioQ Pharma Incorporated
Chief Commercial Officer
+32 474 (053) 253